TNFRSF9 and AL amyloidosis: TNFRSF9 is targeted by Urelumab, currently under investigation for its efficacy against leukemia, multiple myeloma, malignant tumors, solid tumors, and B-cell non-Hodgkin’s lymphoma (Supplementary Table S5).